DR. VAMSI KRISHNA MOOTHA, M.D.
Osteopathic Medicine at Cambridge St, Boston, MA

2009006, Mar 12, 2009

Jul 11, 2008

12/172186

David A. Weitz - Bolton MA, US
Andrew Griffiths - Strasbourg, FR
Sarah Koester - Cambridge MA, US
Vamsi K. Mootha - Cambridge MA, US
Honey Duan - Xh Den Haag, NL
Jeremy Agresti - Cambridge MA, US
Christoph Merten - Bottrop, DE
John Heyman - Waltham MA, US
John R. Gilbert - Brookline MA, US

President and Fellows of Harvard College - Cambridge MA

A61K 39/395, C12Q 1/02, G01N 33/53, A01N 1/02

4241301, 435 29, 435 72, 435 2

The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like.

2012001, Jan 19, 2012

Aug 1, 2011

13/195468

David A. Weitz - Bolton MA, US
Andrew Griffiths - Strasbourg, FR
Sarah Koester - Bad Urach, DE
Vamsi K. Mootha - Cambridge MA, US
Honey Duan - Xh Den Haag, NL
Jeremy Agresti - Sacramento CA, US
Christoph Merten - Bottrop, DE
John Heyman - Waltham MA, US
John R. Gilbert - Brookline MA, US

President and Fellows of Harvard College - Cambridge MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

G01N 33/53, G01N 21/64

435 792, 435 71

The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like.

2012013, May 31, 2012

May 14, 2010

13/320348

Vamsi K. Mootha - Boston MA, US
Vishal Gohil - Somerville MA, US
Sunil Sheth - San Mateo CA, US
Yuhua Ji - Redwood City CA, US

The General Hospital Corporation - Boston MA

A61K 31/495, C12Q 1/48, A61P 9/10, A61P 33/06, A61P 25/16, A61P 13/12, A61P 33/00, A61P 33/02, G01N 33/53, A61P 25/28

51425504, 435 78, 435 15

Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.

2009014, Jun 4, 2009

Jun 13, 2008

12/157824

Vamsi Krishna Mootha - Cambridge MA, US
Bridget Wagner - Medford MA, US
Toshimori Kitami - Cambridge MA, US

A61K 38/28, A61K 31/4184, A61K 31/407, A61K 31/352, A61K 31/12, A61K 31/337, A61K 31/357, C12Q 1/68, C07H 21/00, C12Q 1/34, A61K 31/4748, A61K 31/475, A61P 3/04, A61P 3/10, A61P 25/00, A61P 9/00

514 4, 514395, 514411, 514456, 514685, 514449, 514463, 514281, 514285, 435 6, 435 18, 536 2433

The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.

2011031, Dec 22, 2011

Jul 7, 2009

13/002815

Thomas Wang - Lexington MA, US
Oded Shaham - Cambridge MA, US
Robert Gerszten - Brookline MA, US
Vamsi K. Mootha - Cambridge MA, US
Vasan S. Ramachandran - Berlin MA, US
Martin Larson - Chestnut Hill MA, US

A61K 38/28, G01N 33/74, A61K 38/26, H01J 49/26, A61K 31/19, A61K 33/24, A61P 3/10, G01N 33/53, C12Q 1/54

424646, 435 792, 436501, 514 72, 435 14, 514 59, 514557, 250282

The invention, in some aspects, relates to methods for characterizing glucose-related metabolic disorders. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling, and treating glucose-related metabolic disorders. In some aspects, the invention relates to methods useful for diagnosing, classifying, profiling, and treating diabetes.